Kiora Pharmaceuticals signs exclusive CKD license effective Aug. 20, 2026
Kiora Pharmaceuticals enters an exclusive license agreement with CKD effective August 20, 2026, with CKD paying Kiora $1M up-front and eligible for double digit royalties on KIO-301 net sales in South Korea.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.